The contribution of cannabis use to the increased psychosis risk among minority ethnic groups in Europe.

Africa Caribbean Surinam aetiology amphetamine cannabis cocaine ethnicity migration pathogenesis psychotic disorder schizophrenia

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
09 May 2024
Historique:
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe. We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of migrants compared with the local reference population, without and with adjustment for measures of cannabis use. The OR of psychotic disorder for non-western minorities, adjusted for age, sex, and recruitment area, was 1.80 (95% CI 1.39-2.33). Further adjustment of this OR for frequency of cannabis use had a minimal effect: OR = 1.81 (95% CI 1.38-2.37). The same applied to adjustment for frequency of use of high-potency cannabis. Likewise, adjustments of ORs for most sub-groups of non-western countries had a minimal effect. There were two exceptions. For the Black Caribbean group in London, after adjustment for frequency of use of high-potency cannabis the OR decreased from 2.45 (95% CI 1.25-4.79) to 1.61 (95% CI 0.74-3.51). Similarly, the OR for Surinamese and Dutch Antillean individuals in Amsterdam decreased after adjustment for daily use: from 2.57 (95% CI 1.07-6.15) to 1.67 (95% CI 0.62-4.53). The contribution of cannabis use to the excess risk of psychotic disorder for non-western minorities was small. However, some evidence of an effect was found for people of Black Caribbean heritage in London and for those of Surinamese and Dutch Antillean heritage in Amsterdam.

Sections du résumé

BACKGROUND BACKGROUND
We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe.
METHODS METHODS
We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of migrants compared with the local reference population, without and with adjustment for measures of cannabis use.
RESULTS RESULTS
The OR of psychotic disorder for non-western minorities, adjusted for age, sex, and recruitment area, was 1.80 (95% CI 1.39-2.33). Further adjustment of this OR for frequency of cannabis use had a minimal effect: OR = 1.81 (95% CI 1.38-2.37). The same applied to adjustment for frequency of use of high-potency cannabis. Likewise, adjustments of ORs for most sub-groups of non-western countries had a minimal effect. There were two exceptions. For the Black Caribbean group in London, after adjustment for frequency of use of high-potency cannabis the OR decreased from 2.45 (95% CI 1.25-4.79) to 1.61 (95% CI 0.74-3.51). Similarly, the OR for Surinamese and Dutch Antillean individuals in Amsterdam decreased after adjustment for daily use: from 2.57 (95% CI 1.07-6.15) to 1.67 (95% CI 0.62-4.53).
CONCLUSIONS CONCLUSIONS
The contribution of cannabis use to the excess risk of psychotic disorder for non-western minorities was small. However, some evidence of an effect was found for people of Black Caribbean heritage in London and for those of Surinamese and Dutch Antillean heritage in Amsterdam.

Identifiants

pubmed: 38721761
doi: 10.1017/S0033291724001004
pii: S0033291724001004
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

J P Selten (JP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Research, GGZ Rivierduinen, Leiden, The Netherlands.

M Di Forti (M)

Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

D Quattrone (D)

Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

P B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, UK.
CAMEO Early Intervention Service, Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, England.

H E Jongsma (HE)

Centre for Transcultural Psychiatry 'Veldzicht', Balkbrug, The Netherlands.
VR Mental Health Lab, University Centre for Psychiatry, University Medical Centre Groningen, Groningen, The Netherlands.

C Gayer-Anderson (C)

Department of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK.

A Szöke (A)

Univ Paris Est Creteil, INSERM, IMRB, AP-HP, Hopitaux Universitaires "H. Mondor", DMU IMPACT, Fondation Fondamental, F-94010 Creteil, France.

P M Llorca (PM)

EA 7280 Npsydo, Université Clermont Auvergne, Clermont-Ferrand, France.

C Arango (C)

Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Madrid, Spain.

M Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), CIBERSAM, ISCIII, Barcelona, Spain.

J Sanjuan (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental, Valencia, Spain.

J L Santos (JL)

Department of Psychiatry, Hospital "Virgen de la Luz", Cuenca, Spain.

M Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain.

I Tarricone (I)

Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorium Università di Bologna, Bologna, Italy.

D Berardi (D)

Alma Mater Studiorium Università di Bologna, Bologna, Italy.

A Lasalvia (A)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.

S Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

C la Cascia (C)

Department of Biomedicine, Neuroscience and advanced Diagnostic (BiND), Psychiatry section, University of Palermo, Palermo, Italy.

E Velthorst (E)

Department of Research, GGZ Noord-Holland-Noord, Heerhugowaard, The Netherlands.

E M A van der Ven (EMA)

Department of Clinical, Neuro- and Developmental Psychology, Vrije Universiteit Amsterdam, The Netherlands.

L de Haan (L)

Early Psychosis Section, Department of Psychiatry, Amsterdam UMC. Location Academic Medical Centre, University of Amsterdam, The Netherlands.

B P Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

J van Os (J)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Psychiatry, Brain Center Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.

J B Kirkbride (JB)

PsyLife Group, Division of Psychiatry, UCL, London, UK.

C M Morgan (CM)

ESRC Centre for Society and Mental Health, King's College London, London, UK.

R M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.

F Termorshuizen (F)

Department of Research, GGZ Rivierduinen, Leiden, The Netherlands.

Classifications MeSH